ArticleInfluenza and other respiratory viruses2025

Cost-Effectiveness Analysis of Nirsevimab for Respiratory Syncytial Virus Disease Prevention in Newborns of Hong Kong.

Yingcheng Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.